Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia

Area of Science:

• Cardiology
• Pharmacology

Background:

• Anagrelide is a phosphodiesterase-3 inhibitor used to treat essential thrombocythaemia.
• Cardiovascular adverse events, though rare, can be severe and potentially fatal.

Observation:

• This case involves a 78-year-old woman with essential thrombocythaemia recently prescribed anagrelide.
• The patient presented with syncope, bruising, and facial trauma.

Findings:

• The patient developed ventricular tachyarrhythmia, a serious cardiac side effect of anagrelide.
• Cardiotoxicity from anagrelide is linked to increased cyclic AMP, causing positive inotropic and chronotropic effects.
• These effects are often reversible upon discontinuation of the drug.

Implications:

• Awareness of potential cardiotoxicity is crucial for patients starting anagrelide, especially the elderly.
• Early recognition and cessation of anagrelide may prevent severe cardiovascular outcomes.
• Further research into monitoring and managing anagrelide-induced cardiotoxicity is warranted.